Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metyrosine SCHEMBL50398 | 1.00 | BLM (1.00) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL5053839 | 1.00 | BLM (1.00) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Racemetyrosine SCHEMBL61871 | 1.00 | BLM (1.00) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL3020472 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL27799143 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL29435134 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL6254539 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Racemetyrosine SCHEMBL28095637 | 0.95 | BLM (0.90) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| SCHEMBL24305563 | 0.85 | BLM (0.73) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| SCHEMBL6717498 | 0.85 | BLM (0.73) | BLMALDH1A1CYP3A4KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2170 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119424050-A | Degradable valve frame and heart valve | 元心科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119174751-A | Compositions and methods for treating anxiety-related disorders | 霍夫曼技术有限责任公司 | 2024-12-24 | — | — | CN | claimed |
| CN-113710319-B | Compositions and methods for treating anxiety-related disorders | 霍夫曼技术有限责任公司 | 2024-10-11 | — | — | CN | claimed |
| US-11931329-B2 | Compositions and methods for treating anxiety-related disorders | YAMO PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | claimed |
| US-20240024268-A1 | Methods for Dopamine Modulation in Human Neurologic Diseases | SACKNER BERNSTEIN JONATHAN (US) | 2024-01-25 | — | — | US | claimed |
| US-20240016815-A1 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | HOFFMAN TECHNOLOGIES LLC | 2024-01-18 | — | — | US | claimed |
| US-11806326-B2 | Methods for dopamine modulation in human neurologic diseases | SACKNER BERNSTEIN JONATHAN (US) | 2023-11-07 | — | — | US | claimed |
| US-11786496-B2 | Composition and methods for treating intestinal hyperpermeability | YAMO PHARMACEUTICALS LLC (US) | 2023-10-17 | — | — | US | claimed |
| EP-4255920-A2 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | Hoffman Technologies LLC (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116783212-A | Compositions and methods for modulating cancer in non-human mammals | 霍夫曼技术有限责任公司 | 2023-09-19 | — | — | CN | claimed |
| EP-0742494-A1 | Novolak containing photoresist stripper composition | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1996-11-13 | — | — | EP | claimed |
| US-5507978-A | CORROSION RESISTANCE | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1996-04-16 | — | — | US | claimed |
| US-5472830-A | Mixture of polar organic solvent, amine and hydroxy amino acid | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1995-12-05 | — | — | US | claimed |
| EP-0678788-A2 | Non-corrosive photoresist stripping composition | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| EP-0061356-B1 | ANTAGONISTS OF THE ANTIDIURETIC AND/OR VASOPRESSOR ACTION OF ARGININE VASOPRESSIN | Medical College of Ohio (US) | 1985-07-17 | — | — | EP | claimed |
| US-4367225-A | Novel antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin | THE MEDICAL COLLEGE OF OHIO (US) | 1983-01-04 | — | — | US | claimed |